ArticleBMC geriatrics2026
Psychometric properties of the Turkish version of the Parkinson's disease quality of life-7 (PDQoL-7) in older adults.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06230926 (Turkish Adaptation, Validity and Reliability of "Parkinson's Disease Quality of Life 7), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Turkish Adaptation, Validity and Reliability of "Parkinson's Disease Quality of Life 7 (PDQoL7)" Questionnaire
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson’s disease (PD) is a common neurodegenerative condition in older adults and is associated with substantial impairment in quality of life. In geriatric populations, brief, and reliable disease-specific instruments are particularly important for reducing cognitive and physical burden during assessment. This study aimed to adapt the Parkinson’s Disease Quality of Life-7 (PDQoL-7) into Turkish and to evaluate its validity and reliability in older adults with PD.
methodsThis methodological study included 129 individuals aged 65–90 years with PD who attended a neurology outpatient clinic between November 2023 and February 2025. The translation and cross-cultural adaptation process followed internationally accepted guidelines. Psychometric evaluation included internal consistency assessed by Cronbach’s alpha, test-retest reliability assessed using the intraclass correlation coefficient, construct validity examined through inter-item correlations and confirmatory factor analysis, and concurrent validity evaluated by correlations with the Parkinson’s Disease Questionnaire-39 (PDQ-39) and the Short Form-36 (SF-36).
resultsThe Turkish PDQoL-7 demonstrated excellent test-retest reliability (ICC = 0.970; item ICCs = 0.863–0.947; p < 0.001) and internal consistency (Cronbach’s alpha = 0.928; item-deleted range: 0.913–0.921). Inter-item correlations (0.549–0.724) supported item homogeneity and a unidimensional structure. Confirmatory factor analysis confirmed a one-factor model with strong loadings (0.76–0.90) and good model fit (χ²(14) = 20.47, p = 0.116; CFI = 0.984; TLI = 0.977; RMSEA = 0.060; SRMR = 0.034). Strong correlations were found with PDQ-39 (r = 0.916) and SF-36 general health (r= -0.809).
conclusionThe Turkish version of the PDQoL-7 is a valid and reliable instrument for assessing quality of life in older adults with PD. Its brief structure and strong psychometric properties support its use in geriatric clinical practice and research settings. CLINICAL TRIAL NUMBER: ClinicalTrials.gov, NCT06230926, registered on 19 January 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.